Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r
NCT ID: NCT00476502
Last Updated: 2012-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
250 participants
OBSERVATIONAL
2006-02-28
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics of Low Dose Ritonavir
NCT00622206
A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
NCT00435929
Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg
NCT00476983
TDM of Generic Lopinavir/Ritonavir 200/50 mg
NCT00802334
Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
NCT02652624
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
patients involved in structured interruption therapy
identify genetic polymorphism in Thai HIV infected
Gene sequencing of Cyp450 metabolic pathway
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
identify genetic polymorphism in Thai HIV infected
Gene sequencing of Cyp450 metabolic pathway
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On low-dose ritonavir boosted saquinavir at the time blood samples are collected
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Pharma AG
INDUSTRY
The HIV Netherlands Australia Thailand Research Collaboration
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kiat Ruxrungtham, MD
Role: PRINCIPAL_INVESTIGATOR
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Bangkok, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HIV-NAT 031
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.